Internal Medicine, Hematology & Oncology · Bronx, NY
NPI
1467724286
Since 2012
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
4422 3rd Ave
Bronx, NY, 10457
Phone (718) 960-6205
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,896
121 services
Medicare patients, 2024
50
Average age 72
Drug cost, 2024
$4.4M
970 prescriptions
Company payments, 2025
$3,334
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ivette Vigoda was code 99214 (office e&m - established), 52 times for 25 patients. In total Ivette Vigoda billed 121 services in 13 codes, and Medicare paid $9,896.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-07-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 52 | 25 | $77.70 | $4,041 |
| 99213 Office E&M - Established | Facility | 19 | 14 | $46.16 | $877 |
By year: 2022 $9,807 for 117 services; 2023 $8,201 for 86 services; 2024 $9,896 for 121 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ivette Vigoda prescribed most often to Medicare patients was Darzalex Faspro (Daratumumab-Hyaluronidase-Fihj), with 82 prescriptions and refills. In total Ivette Vigoda wrote 970 Medicare prescriptions that cost $4.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 82 | 82 | Under 11 | $752K |
| Xgeva Denosumab | 72 | 72 | Under 11 | $220K |
| Warfarin Sodium Generic | 65 | 71 | 16 | $162 |
| Anastrozole Generic | 61 | 99 | 11 | $400 |
| Bortezomib Generic | 49 | 49 | Under 11 | $915 |
| Prolia Denosumab | 47 | 282 | 26 | $76K |
| Lupron Depot Leuprolide Acetate | 35 | 104 | 12 | $181K |
| Letrozole Generic | 32 | 74 | 14 | $456 |
| Ondansetron Hcl Generic | 32 | 32 | 18 | $332 |
| Revlimid Lenalidomide | 27 | 27 | Under 11 | $391K |
| Eliquis Apixaban | 23 | 25 | Under 11 | $15K |
| Valacyclovir Valacyclovir Hcl | 17 | 39 | Under 11 | $529 |
| Nubeqa Darolutamide | 15 | 15 | Under 11 | $209K |
| Erleada Apalutamide | 15 | 15 | Under 11 | $221K |
| Imfinzi Durvalumab | 15 | 15 | Under 11 | $179K |
Brand drugs: 490 claims; generic drugs: 480 claims; opioid claims: 30.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ivette Vigoda $3,334 ($3,334 in general payments such as food, travel and fees) from 24 companies. The largest payer was Pfizer Inc. with $417.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 18 | $417 |
| Janssen Biotech, Inc. JNJ | 13 | $335 |
| Novartis Pharmaceuticals Corporation NVS | 14 | $326 |
| Merck Sharp & Dohme LLC MRK | 9 | $227 |
| Daiichi Sankyo Inc. 4568.T | 10 | $223 |
| GlaxoSmithKline, LLC. GSK | 9 | $217 |
| Genzyme Corporation SNY | 8 | $213 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $193 |
| Stemline Therapeutics Inc. | 7 | $151 |
| Gilead Sciences, Inc. GILD | 5 | $143 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.